SG11201501684UA - Use of markers in the identification of cardiotoxic agents - Google Patents

Use of markers in the identification of cardiotoxic agents

Info

Publication number
SG11201501684UA
SG11201501684UA SG11201501684UA SG11201501684UA SG11201501684UA SG 11201501684U A SG11201501684U A SG 11201501684UA SG 11201501684U A SG11201501684U A SG 11201501684UA SG 11201501684U A SG11201501684U A SG 11201501684UA SG 11201501684U A SG11201501684U A SG 11201501684UA
Authority
SG
Singapore
Prior art keywords
markers
identification
cardiotoxic agents
cardiotoxic
agents
Prior art date
Application number
SG11201501684UA
Other languages
English (en)
Inventor
Niven Rajin Narain
Rangaprasad Sarangarajan
Vivek K Vishnudas
Michael Andrew Kiebish
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Llc filed Critical Berg Llc
Publication of SG11201501684UA publication Critical patent/SG11201501684UA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201501684UA 2012-09-12 2013-09-12 Use of markers in the identification of cardiotoxic agents SG11201501684UA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261700327P 2012-09-12 2012-09-12
US201261706611P 2012-09-27 2012-09-27
US201261727104P 2012-11-15 2012-11-15
US201261727115P 2012-11-16 2012-11-16
US201261732105P 2012-11-30 2012-11-30
PCT/US2013/059559 WO2014043421A1 (en) 2012-09-12 2013-09-12 Use of markers in the identification of cardiotoxic agents

Publications (1)

Publication Number Publication Date
SG11201501684UA true SG11201501684UA (en) 2015-04-29

Family

ID=50278696

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201501684UA SG11201501684UA (en) 2012-09-12 2013-09-12 Use of markers in the identification of cardiotoxic agents

Country Status (12)

Country Link
US (1) US10352947B2 (zh)
EP (1) EP2895861A4 (zh)
JP (1) JP6371287B2 (zh)
KR (1) KR20150043566A (zh)
CN (2) CN107255721A (zh)
AU (1) AU2013315371A1 (zh)
CA (1) CA2884637A1 (zh)
HK (1) HK1212767A1 (zh)
IL (1) IL237557A0 (zh)
NZ (1) NZ706155A (zh)
SG (1) SG11201501684UA (zh)
WO (1) WO2014043421A1 (zh)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201609654PA (en) 2012-05-22 2017-01-27 Berg Llc Interrogatory cell-based assays for identifying drug-induced toxicity markers
WO2014166303A2 (en) * 2013-04-12 2014-10-16 The Chinese University Of Hong Kong Use of multiomic signature to predict diabetes
US9589043B2 (en) 2013-08-01 2017-03-07 Actiance, Inc. Unified context-aware content archive system
KR101660328B1 (ko) * 2014-01-14 2016-09-27 한국과학기술연구원 심혈관 질환 진단용 바이오 마커
US9550981B2 (en) 2014-01-22 2017-01-24 University Of Washington Modified tafazzin proteins and methods of making and using the same
ES2676553T3 (es) 2014-03-26 2018-07-20 F. Hoffmann-La Roche Ag IGFBP7 para el diagnóstico de la disfunción diastólica
EP3230308B1 (en) * 2014-12-12 2019-05-01 University of Washington Methods for treating and preventing cardiomyopathy
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
WO2017028308A1 (en) * 2015-08-20 2017-02-23 Bgi Shenzhen Biomarkers for coronary heart disease
CN107543929A (zh) * 2016-06-23 2018-01-05 中国医学科学院肿瘤医院 基于蛋白标志物hsp90ab1诊断肺癌患者的试剂盒
US10880254B2 (en) 2016-10-31 2020-12-29 Actiance, Inc. Techniques for supervising communications from multiple communication modalities
MX2019011064A (es) * 2017-03-15 2020-01-27 Juneau Biosciences Llc Metodos para usar marcadores geneticos asociados con endometriosis.
JP7032723B2 (ja) * 2017-07-21 2022-03-09 公立大学法人福島県立医科大学 薬剤の心毒性評価方法及びそのための試薬又はキット
CN107944226B (zh) * 2017-12-19 2020-03-27 清华大学 基于信息论基因转录本组装与量化方法及系统
CN109908368A (zh) * 2019-01-31 2019-06-21 中国人民解放军军事科学院军事医学研究院 一种senp1基因和/或senp1蛋白在制备治疗心血管疾病药物中的应用
US11216742B2 (en) 2019-03-04 2022-01-04 Iocurrents, Inc. Data compression and communication using machine learning
CN110093412A (zh) * 2019-03-29 2019-08-06 南方医科大学南方医院 用于诊断动脉粥样硬化的分子标志物ugp2及应用
CN110201152B (zh) * 2019-06-05 2021-08-27 重庆大学 一种G3bp2多肽疫苗及应用
JP2023501515A (ja) * 2019-11-12 2023-01-18 テクニッシェ ウニヴェルズィテート ミュンヘン ヒトＩＬ－２７αサブユニットの均質ムテイン
CN110850086B (zh) * 2019-11-18 2023-05-02 西安交通大学 一种肝移植术后缺血性胆道病变血清诊断标志物acly的应用
WO2021108380A1 (en) * 2019-11-26 2021-06-03 Ohio State Innovation Foundation Methods and compositions for cardiovascular disease detection and management
CN111710425A (zh) * 2020-06-19 2020-09-25 复旦大学附属中山医院 一种免疫检查点抑制剂心脏毒性评估方法，系统及装置
KR20220082558A (ko) * 2020-12-10 2022-06-17 재단법인 의약바이오컨버젼스연구단 면역 증진 활성이 있는 신규 crs 단편 펩타이드 및 이의 용도
CN112608923B (zh) * 2021-01-17 2023-05-12 上海捷瑞生物工程有限公司 一种抑制ddx17相关rna表达产物的核苷酸及其应用
CN115112776B (zh) * 2021-03-18 2023-07-04 中国科学院大连化学物理研究所 联合标志物及在诊断心房颤动中应用及诊断试剂或试剂盒
CN113621698A (zh) * 2021-08-08 2021-11-09 华中科技大学同济医学院附属协和医院 Flnc基因突变体及其应用
CN115011681B (zh) * 2021-12-31 2023-04-18 河南省人民医院 肥厚型心肌病相关的标志分子及其在诊断肥厚型心肌病中的应用
CN114705859B (zh) * 2022-04-26 2023-02-24 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种用于肝癌骨转移诊断、治疗和预后的生物标志物及其应用
WO2023239197A1 (ko) * 2022-06-09 2023-12-14 주식회사 자이메디 면역 증진 활성이 있는 신규 crs 단편 펩타이드 및 이의 용도
CN117393154B (zh) * 2023-12-12 2024-03-01 中国中医科学院医学实验中心 基于血清全通路氧化脂质组学筛选心力衰竭生物标志物的方法及应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6951924B2 (en) 1997-03-14 2005-10-04 Human Genome Sciences, Inc. Antibodies against secreted protein HTEBYII
ES2523856T3 (es) 2000-12-22 2014-12-02 Lpath, Inc. Anticuerpos de esfingosina-1-fosfato para el tratamiento de enfermedades asociadas con elevadas concentraciones de esfingolípidos
US7447594B2 (en) 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
US20070054269A1 (en) 2001-07-10 2007-03-08 Mendrick Donna L Molecular cardiotoxicology modeling
CA2452897A1 (en) 2001-07-10 2003-08-21 Gene Logic, Inc. Cardiotoxin molecular toxicology modeling
KR20040064275A (ko) * 2001-11-09 2004-07-16 소스 프리시전 메디슨, 인코포레이티드 유전자 발현 프로파일을 이용한 질병의 동정, 모니터링,치료 및 생물학적 상태의 확인
ES2222775B1 (es) * 2002-01-31 2006-12-16 Laboratorios Indas, S.A. Procedimiento para la deteccion de una predisposicion a una enfermedad cardiovascular.
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US20040137544A1 (en) 2002-10-31 2004-07-15 Roberto Latini PTX3 as an early prognostic indicator of cardiovascular and cerebrovascular pathologies
US8263325B2 (en) 2002-11-15 2012-09-11 Ottawa Heart Institute Research Corporation Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis
GB0229747D0 (en) * 2002-12-20 2003-01-29 Axis Shield Asa Assay
US20090169585A1 (en) 2003-10-23 2009-07-02 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Their Use In Modulating Gene Product Concentration Or Activity
WO2005053728A2 (de) 2003-12-01 2005-06-16 Xantos Biomedicine Ag Mit adipositas assoziierte proteine und deren verwendung in therapie und diagnostik
JP4625812B2 (ja) * 2003-12-05 2011-02-02 ザ クリーブランド クリニック ファウンデーション 心臓血管疾患に対するリスクマーカー
JP4667372B2 (ja) * 2004-02-25 2011-04-13 株式会社ペルセウスプロテオミクス 血管障害の程度の判定方法
US7883858B2 (en) 2005-01-27 2011-02-08 Institute For Systems Biology Methods for identifying and monitoring drug side effects
US9002652B1 (en) 2005-01-27 2015-04-07 Institute For Systems Biology Methods for identifying and using organ-specific proteins in blood
EP1907582B1 (en) * 2005-07-27 2012-01-04 Oncotherapy Science, Inc. Ect2 as a therapeutic target for esophageal cancer
WO2007084187A2 (en) 2005-08-26 2007-07-26 Gene Logic, Inc. Molecular cardiotoxicology modeling
EP1996718B1 (en) 2006-03-06 2011-11-30 Ceetox Inc. Toxicity screening methods
US9353415B2 (en) * 2006-12-19 2016-05-31 Thomson Reuters (Scientific) Llc Methods for functional analysis of high-throughput experimental data and gene groups identified therefrom
US20100278787A1 (en) 2007-07-18 2010-11-04 Cellartis Ab Cardiomyocyte-like cell clusters derived from hbs cells
EP2019318A1 (en) * 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
CA2699908C (en) * 2007-09-20 2012-09-11 Resveratrol Partners, Llc Resveratrol-containing compositions for modulating gene product concentration or activity
WO2009075566A1 (en) * 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Biomarkers for cardiovascular disease
WO2010032007A1 (en) 2008-09-18 2010-03-25 Universitetet I Oslo Use of ctgf as a cardioprotectant
EP2440936A4 (en) 2009-06-08 2013-03-13 Singulex Inc GROUPS OF HIGHLY SENSITIVE BIOMARKERS
EP2944964B1 (en) * 2009-11-27 2018-01-10 Baker IDI Heart and Diabetes Institute Holdings Ltd Lipid biomarkers for stable and unstable heart disease
US20120058088A1 (en) 2010-06-28 2012-03-08 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Methods Of Use
WO2012024296A1 (en) 2010-08-20 2012-02-23 University Of Miami Arterial repair with cultured bone marrow cells and whole bone marrow
JP5930266B2 (ja) 2010-08-26 2016-06-08 国立研究開発法人医薬基盤・健康・栄養研究所 遺伝子絞り込み装置、遺伝子絞り込み方法、及びコンピュータプログラム
CN102520192B (zh) * 2011-12-29 2014-08-13 深圳康美生物科技股份有限公司 一种定量检测肌钙蛋白i/肌酸激酶同工酶/肌红蛋白的荧光免疫层析试剂盒
SG10201609654PA (en) 2012-05-22 2017-01-27 Berg Llc Interrogatory cell-based assays for identifying drug-induced toxicity markers

Also Published As

Publication number Publication date
CN104781670A (zh) 2015-07-15
US10352947B2 (en) 2019-07-16
KR20150043566A (ko) 2015-04-22
US20140100128A1 (en) 2014-04-10
JP2015529335A (ja) 2015-10-05
AU2013315371A1 (en) 2015-04-09
IL237557A0 (en) 2015-04-30
CA2884637A1 (en) 2014-03-20
HK1212767A1 (zh) 2016-06-17
WO2014043421A1 (en) 2014-03-20
NZ706155A (en) 2018-09-28
JP6371287B2 (ja) 2018-08-08
EP2895861A4 (en) 2016-06-22
CN104781670B (zh) 2017-07-07
CN107255721A (zh) 2017-10-17
EP2895861A1 (en) 2015-07-22

Similar Documents

Publication Publication Date Title
HK1212767A1 (zh) 標誌物用於識別心臟毒性劑的用途
HK1203493A1 (zh) 取代的氮雜雙環及其用途
HK1209332A1 (zh) 細胞凋亡誘導劑
HK1199023A1 (zh) 取代的苯並噻吩基-吡咯並三嗪及其用途
IL236616B (en) 5-aminotetrahydroquinoline-2-carboxylic acids and their use
HK1200822A1 (zh) 取代的聯吡啶胺及其用途
IL239643A0 (en) Converted morphines and their use
HRP20160796T1 (hr) Biciklički supstituirani uracili i njihovo korištenje
HK1208687A1 (zh) 結合劑及其用途
EP2828258A4 (en) NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE
HK1198646A1 (zh) 取代的咪唑並噠嗪類化合物及其用途
GB201216649D0 (en) Agents and methods
HK1203198A1 (zh) 取代的苯基咪唑並吡唑及其用途
HK1202859A1 (zh) 抗瘧劑
ZA201408094B (en) Anti-malarial agents
GB201204014D0 (en) Diagnostic marker compounds and their use
FR2996926B1 (fr) Surface magneto-optique
HK1207154A1 (zh) -脂聯素複合物及其用途
EP2922862A4 (en) COMPLEX FORMING MODULATING ACTIVE SUBSTANCES AND USES THEREOF
GB201213726D0 (en) Novel compounds and their use
GB201204745D0 (en) Identifying proximity and location
RS55201B1 (sr) Antimalarijski agensi
GB201223415D0 (en) 'Sand table' wobble free table and sandfoot
GB201214749D0 (en) Compounds and their uses
GB201209458D0 (en) Novel compounds and their use as kinase inhibitors